Project Grant K08CA290152
Award Date
3/1/25
Completion Date
2/28/30
Dollars Obligated
$282K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94143, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) provides $270,981 to The University of Texas Southwestern Medical Center to conduct research on overcoming resistance to immunotherapies in hepatobiliary cancers. The grant supports a 5-year research program that aims to: Conduct a Phase 2 clinical trial evaluating an anti-TIGIT antibody in combination with anti-PD-1 therapy for hepatobiliary cancers refractory to PD-1 blockade....
The National Cancer Institute (NCI) awarded a $145,336 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Sloan-Kettering Institute for Cancer Research. The grant, with a performance period from March 1, 2025 to February 28, 2027, will support research to metabolically reprogram hepatic macrophages to overcome the "immune-desert" phenotype of B-catenin-driven hepatocellular carcinoma. The project aims to determine how TSC1-deficient hepatic macrophages can...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) supports research to study the role of tumor-associated plasmacytoid dendritic cells (TAPDC) in the tumor immune microenvironment of liver cancer or hepatocellular carcinoma (HCC) in the context of HIV infection. The $634,061 award to the University of Maryland, Baltimore aims to: 1) characterize how TAPDC reprogram the HCC tumor immune microenvironment, including the impact of HIV...
This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) provides $196,029 to the University of Massachusetts Medical School (UMass Medical) to conduct research aimed at deciphering the immune evasion mechanisms associated with mutant isocitrate dehydrogenase 1 (mIDH1) in various solid tumors, including intrahepatic cholangiocarcinoma. The research focuses on two key objectives: 1) Elucidating the role of viral mimicry in the response to mIDH1...
This $138,742 Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports a research project at The Johns Hopkins University to investigate how combination immunotherapy alters cellular communication networks in pancreatic ductal adenocarcinoma (PDAC). The key objectives are to: 1) develop statistical methods to identify differential cellular interactions between immunotherapy treatment groups using single-cell RNA sequencing data from PDAC clinical...
This National Cancer Institute (NCI) federal Project Grant award, under the Cancer Research Manpower (CFDA 93.398) program, provides $171,135.00 to Weill Medical College of Cornell University to develop and test a multi-level intervention to improve access to timely, curative treatment for patients with small hepatocellular carcinoma (HCC), a type of liver cancer. The key objectives of this 5-year project are to: 1) identify barriers and facilitators to timely small HCC treatment using...
This Project Grant award, funded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), supports research to develop novel, biologic RNA molecules that can modulate metabolism in hepatocellular carcinoma (HCC), the most common form of liver cancer. The University of California, Davis is the prime awardee, receiving $483,591 over the 5-year project period from August 1, 2024 to July 31, 2029. The key objectives are to: (1) design, clone, express, and...
The National Cancer Institute (NCI) awarded a $232,515 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to Loyola University of Chicago's Health Sciences Campus to DEFINE THE MOLECULAR MECHANISMS IN AND IDENTIFY BIOMARKERS FOR FAK-DRIVEN HEPATOCELLULAR CARCINOMA. The study aims to (1) determine the mechanism through which the protein Focal Adhesion Kinase (FAK) promotes the expression of Connective Tissue Growth Factor (CTGF) in hepatocellular carcinoma (HCC), (2)...
This federal Project Grant award in the amount of $402,400.00 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will support research to investigate targeting neutrophilic myeloid-derived suppressor cells (PMN-MDSCs) as a potential therapeutic approach for treating hepatoblastoma, the most common primary liver cancer in children. The research, conducted by the University of Hawaii at Manoa, aims to determine the specific oncogenes that drive the recruitment of...
This federal Project Grant award, funded by the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398), supports research to understand the role of the enzyme HDAC11 in liver cancer progression and evaluate new HDAC11 inhibitors as potential cancer treatments. The $127,952 award to George Washington University will test the hypothesis that HDAC11 promotes liver cancer by regulating alternative mRNA splicing through de-fatty acylation of the splicing factor SF3B2. The...